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Abstract
Background: Acute malnutrition is a continuum condition, but severe and moderate forms are treated separately,
with different protocols and therapeutic products, managed by separate United Nations agencies. The Combined
Protocol for Acute Malnutrition Study (ComPAS) aims to simplify and unify the treatment of uncomplicated severe
and moderate acute malnutrition (SAM and MAM) for children 6–59 months into one protocol in order to improve
the global coverage, quality, continuity of care and cost-effectiveness of acute malnutrition treatment in resource-
constrained settings.
Methods/design: This study is a multi-site, cluster randomized non-inferiority trial with 12 clusters in Kenya and 12
clusters in South Sudan. Participants are 3600 children aged 6–59 months with uncomplicated acute malnutrition.
This study will evaluate the impact of a simplified and combined protocol for the treatment of SAM and
MAM compared to the standard protocol, which is the national treatment protocol in each country. We will
assess recovery rate as a primary outcome and coverage, defaulting, death, length of stay, average weekly
weight gain and average weekly mid-upper arm circumference (MUAC) gain as secondary outcomes. Recovery
rate is defined across both treatment arms as MUAC ≥125 mm and no oedema for two consecutive visits.
Per-protocol and intention-to-treat analyses will be conducted.
Discussion: If the combined protocol is shown to be non-inferior to the standard protocol, updating guidelines to
use the combined protocol would eliminate the need for separate products, resources and procedures for MAM
treatment. This would likely be more cost-effective, increase availability of services, enable earlier case finding and
treatment before deterioration of MAM into SAM, promote better continuity of care and improve community
perceptions of the programme.
Trial registration: ISRCTN, ISRCTN30393230. Registered on 16 March 2017.
Keywords: Non-inferiority, Acute malnutrition, Cluster randomized trial, Community-based management of acute
malnutrition, Mid-upper arm circumference, Ready-to-use therapeutic food, Kenya, South Sudan
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Background
Acute malnutrition is a major global public health problem
affecting an estimated 52 million children under 5 years of
age [1]. Of these, some 35 million have moderate acute mal-
nutrition (MAM) and 17 million have severe acute malnu-
trition (SAM). The true burden of disease is however likely
much higher. This is because most current estimates are
based on cross-sectional survey data giving prevalence fig-
ures, whereas SAM and MAM, being short-lasting condi-
tions, should ideally be assessed in terms of incidence [2, 3].
Malnutrition in all its forms is an underlying cause of 3.1
million (45%) of deaths among children under 5, with wast-
ing alone responsible for 875,000 child deaths per year [4].
Despite the availability of effective, evidence-based
treatment programmes, especially for SAM, their public
impact is often limited by low coverage of the affected
population. According to recent estimates, less than 20%
of children with SAM receive the treatment they need
[5]. Figures for MAM programme coverage are un-
known—but are likely to be lower since it is often per-
ceived to be less of a priority compared to SAM. This is
despite wasting, the major manifestation of both SAM
and MAM, being on a continuum, with the cut-off be-
tween the two defined statistically (based on weight-for-
height/length standard deviations from the median) ra-
ther than by any distinguishable clinical changes.
In humanitarian settings (as well as many other non-
emergency but fragile contexts where malnutrition is com-
mon), current international and national recommendations
involve treating SAM and MAM in separate programmes,
using separate protocols and separate products managed by
two large but separate United Nations agencies. SAM is
treated with ready-to-use therapeutic food (RUTF) in an
outpatient therapeutic programme (OTP), with oversight
and technical guidance from the United Nations Inter-
national Children’s Fund (UNICEF). MAM is treated with
ready-to-use supplementary food (RUSF) or fortified corn
soy blend ++ (CSB++) in a supplementary feeding
programme (SFP), with oversight and technical guidance
from the World Food Programme (WFP). The shortcom-
ings of this system include the following: (1) it is logistically
complicated to implement, requiring the procurement of
two different nutritional products and the set-up of two
separate programs, in coordination with two separate UN
agencies, (2) it is consequently expensive, and (3) it often
results in the prioritization of SAM over MAM: many aid
agencies and governments offer treatment only of SAM
due to the challenges associated with procuring two prod-
ucts and coordinating two programmes. This results in a
situation where treatment may not be available to children
with MAM until they deteriorate to SAM.
Responding to these current challenges, the Combined
Protocol for Acute Malnutrition Study (ComPAS) will
assess the effectiveness of a simplified, combined
protocol for the treatment of uncomplicated SAM and
MAM for children 6–59 months. The study aims to im-
prove the quality, coverage, continuity and cost-
effectiveness of care (Fig. 1). The combined protocol
uses one product (RUTF) for both SAM and MAM, at
doses designed to optimize growth and minimize cost at
each stage of treatment. Admission and discharge is
assessed using only mid-upper arm circumference
(MUAC) and oedema [6]. Differences between the com-
bined and standard protocol are presented in Table 1.
ComPAS was inspired by increasing realization that
combining the treatment of SAM and MAM makes
biological sense—since wasting is a continuum condition
rather than two distinct and different problems; oper-
ational and financial sense—since staff skill set and infra-
structure are very similar for the two programmes and
may thus usefully be shared; and public health sense—
since a combined programme should be easier to access
and should thus improve overall programme coverage.
Early data supporting the hypothesis of clinical non-
inferiority comes from a 2013 Washington University trial
in Sierra Leone [7]. This study explored the efficacy of an
integrated SAM/MAM treatment protocol using one
product (RUTF) but at different doses for children
<115 mm (175 kcal/kg/day) and 115 to <125 mm
(75 kcal/kg/day). Controls followed standard care guide-
lines: RUTF for SAM and SFP with CSB++ for MAM. Re-
sults showed that the integrated programme had a
reduced caseload of SAM, due to earlier treatment of chil-
dren presenting as MAM, with a similar recovery rate
(83% vs. 79%) and higher coverage (71% vs. 55%, p = 0.
0005). Children who received integrated management re-
covered more rapidly, with greater MUAC gain and higher
weight-for-height Z-score (WHZ) upon discharge.
Other data supporting the use of a single nutritional
product but at different doses comes from our own second-
ary analysis of routine nutrition programme data from five
countries (Yemen, Pakistan, South Sudan, Chad, Kenya)
and three different agencies (International Rescue Commit-
tee (IRC), Action Against Hunger—USA (ACF-USA), and
Médecins Sans Frontières—France (MSF-France)) [8]. This
analysis used observational data to assess the rate of growth
of children recovering from acute malnutrition in OTPs
and SFPs in order to determine energy requirements and
propose an optimized dose of RUTF that correlates with
the MUAC category. We found that:
 Growth trends in MUAC mirror those of
proportional weight gain and rates of MUAC and
weight gain slow with increasing MUAC.
 As the rates of MUAC and weight gain slow,
proportional energy needs decrease.
 Total energy needs of 95% of all children with a
MUAC <125 mm can be met with 1000 kcal/day.
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Based on these observations, the combined and simpli-
fied MUAC-based dosage protocol was developed, and it
is this which is being tested in the current study:
 Children with a MUAC <115 mm and/or oedema
receive two sachets of RUTF per day (1000 kcal).
 Children with a MUAC 115 to <125 mm receive
one sachet of RUTF per day (500 kcal).
The objective of our current project is to assess the ef-
fectiveness of a combined SAM/MAM protocol com-
pared to standard care (separate SAM/MAM treatment)
in two countries: Kenya and South Sudan. The outcomes
of stage 2 are described in Table 2.
We will add to the available evidence by (1) testing a
dosing protocol based on the MUAC category, not
weight [6, 9, 10]; (2) comparing against a control SFP
using RUSF, instead of CSB++; (3) comparing equivalent
definitions of recovery in both control and intervention
groups; (4) using a larger sample size across two coun-
tries; and (5) conducting a thorough cost-effectiveness
analysis using proven methodologies.
The publication of this study protocol aims to improve
transparency and share information to support the de-
velopment of similar studies that seek to simplify the
protocols for acute malnutrition and increase the avail-
ability of treatment.
Methods/design
Trial design
The study is a multi-country cluster randomized con-
trolled non-inferiority trial. The units of randomization
are health facilities stratified by country and then ran-
domly assigned to the control or intervention group.
Children in the control group receive the standard
protocol while those in the intervention group receive
the combined protocol. The study includes a total of 24
clusters, 12 in each country.
Hypothesis
We hypothesize that the combined protocol will be as
effective as the standard protocol in the treatment of
severe and moderate acute malnutrition as measured by
recovery rate, length of stay, average weekly weight and
MUAC gain, and coverage. The combined protocol will
be more cost-effective than the standard protocol. Dif-
ferences between the combined and standard protocols
are presented in Table 2.
Study site and population
There are two sites in this multi-center cluster random-
ized trial: Aweil East, South Sudan and Nairobi, Kenya.
Aweil East is a rural setting in the former state of North-
ern Bahr el Ghazal with a total population of 309,921
and an under five population of 59,574 according to the
most recent national population and housing census in
2008. ACF-USA supports 16 malnutrition clinics in the
area; each is approximately 20–30 km apart. At the time
the study was initiated, only 12 of these clinics were sup-
ported by ACF-USA, and these 12 were all selected for
inclusion in the study.
Nairobi county is an urban area with a total population
of approximately 3.1 million, of which 13% are children
under 5 years, according to the 2009 population census.
Three sub-counties of Nairobi were selected in collabor-
ation with the Ministry of Health (MoH) based on a high
burden of malnutrition and a need for nutritional support
(Embakasi North, Embakasi South and Embakasi West).
Out of the 32 health facilities in the three sub-counties, 12
health facilities were selected based on the following key
factors: the level of care provided (hospitals and dispensar-
ies excluded), the type of care provided (routine child
Fig. 1 ComPAS conceptual framework
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health services available), the population served (slum or
peri-urban communities), and expected caseload of mal-
nutrition. Each treatment facility is approximately 3–5 km
apart. The clinics in Nairobi are run by the MoH, and the
IRC supports with research staff at each clinic to imple-
ment the ComPAS trial.
Eligibility
Children 6–59 months with uncomplicated acute malnutri-
tion are eligible for inclusion in the study per the following
criteria:
 MUAC <125 mm
and/or
 Bilateral pitting oedema (+/++)
and
 Passes the appetite test (consumption of 30 g of
RUTF within 20 min)
and
 No medical complications (i.e. no features of severe
illness as defined by the Integrated Management of
Table 1 Nutritional protocol for the control and intervention trial arms
Standard protocol (control) Combined protocol (intervention)
Admission criteria OTP • MUAC <125 mm
and/or
• Bilateral pitting oedema (+/++)
and
• Clinically uncomplicateda
• WHZ <−3
and/or
• MUAC <115 mm
and/or
• Bilateral pitting oedema (+/++)
and
• Clinically uncomplicateda
SFP
• Discharged from OTP
and/or
• WHZ <−2 to >−3
and/or
• MUAC 115 to <125 mm
and
• Clinically uncomplicateda
Treatment frequency OTP MUAC <115 mm and/or oedema (+/++)
Weekly
SFP MUAC 115 to <125 mm
14 days
Treatment transition criteria ▪ Child meets OTP ‘cured’ definition
as described below
• Two consecutive MUAC measurements
at or above 115 mm
and
• No oedema
Dosage OTP MUAC <115 mm and/or oedema (+/++)
RUTF 200 kcal/kg/day RUTF 1000 kcal/day (2 sachets/day)
SFP MUAC 115 to <125 mm
RUSF 500 kcal/day (1 sachet/day) RUTF 500 kcal/day (1 sachet/day)
Cured OTP ≥125 mm for 2 consecutive measurements
and no oedema▪ Child maintains MUAC ≥115 mm
for 2 consecutive visitsb
and/or
▪ WHZ >−3 for 2 consecutive visitsb
and
▪ No oedema for 2 consecutive visits
SFP
Child maintains WHZ >−2 and/or MUAC
≥125
mm for a period of 2 consecutive visitsb
aClinically uncomplicated: passes the appetite test, no Integrated Management of Childhood Illness (IMCI) danger signs [11]/no serious medical complications
bDependent on which criteria the child was admitted on
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Childhood Illness (IMCI) [11], e.g. no severe nausea/
vomiting, no severe dehydration, no severe pneumonia)
A child is excluded from the study if he or she has
ever been enrolled in the ComPAS trial or if he or she is
receiving SAM or MAM treatment elsewhere, unless he
or she was recently discharged from SAM treatment in
order to attend MAM treatment.
Informed consent procedure
Consent is sought at two levels: at the level of the cluster,
by the health facility officer in charge of each clinic prior
to cluster randomization, and at the level of the individual,
by the caretaker of each child prior to enrolment. When a
caretaker arrives to any health facility included in the
ComPAS trial seeking treatment for their malnourished
child, they are seen by a community health or nutrition
worker to confirm that they are eligible to receive treat-
ment (i.e. they have a MUAC <125 mm, and/or a WHZ <
−2, and/or oedema). Once their eligibility for treatment is
confirmed, they are seen by the ComPAS research officer
and clinical officer responsible for their care. First, the re-
search officer will confirm that the present caretaker is a
primary guardian for the child. If yes, the research officer
describes the aims of the study as detailed in the ‘partici-
pant information sheet’, ensuring that the caretaker feels
comfortable and understands the information. The partici-
pant information sheet provides details of the treatments
provided in the study. The research officer will ensure the
caretaker understands that treatment is available for all
malnourished children regardless of whether they choose
to participate in the study. Caretakers who agree to par-
ticipate in the study will indicate their consent by signing
a written consent form. If caretakers are not able to read
or write, an impartial witness will oversee the consent
process and attest to the caretaker’s verbal consent. If the
caretaker is not a primary guardian or chooses not to par-
ticipate in the study, their child is enrolled for treatment
only, and their information is not collected.
Randomization and blinding
Sequence generation
Randomization sequence is generated using an online
sequence generator [12].
Type
There is stratification by country to ensure equal, 1:1
distribution of control and intervention clinics (clusters)
in each country.
Allocation concealment mechanism and implementation
Clinics agree to participate understanding that group allo-
cation is unknown in advance and is allocated randomly.
The study statistician applies the random number se-
quence to a pre-written list of participating clinics, and the
study team conveys the resultant allocation to the clinic
staff. Individual carers attending clinics for the first time
are very unlikely to know in advance whether their local
clinic is in the intervention or control arm of the study.
Blinding
Due to the nature of intervention, this is not a fully blinded
study. Front-line clinical and study staff must know
whether they are treating children according to interven-
tion or control (standard care) protocols, and the same staff
enrol, manage and follow up patients. Staff in the standard
protocol clinics were given refreshing trainings to reinforce
standard protocol implementation, and staff in the com-
bined protocol clinics were given trainings to roll out the
new protocol. Staff in the clinics do not have access to
overall treatment outcomes for each clinic or each arm of
the trial; they are only aware of individual outcomes for the
children they are responsible for treating. Similarly, individ-
ual carers cannot be blinded to the intervention being given
to their child. Important to note however is that inter-
group differences are unlikely to be striking to anyone but
expert observers: both study arms use nutrient-dense food
pastes, with RUTF and RUSF being peanut-based with
similar taste and appearance; children are measured and
Table 2 Outcomes
Measurement variable Analysis metric Method of aggregation Time point
Primary
Recovery MUAC ≥125 mm and no oedema Final value Proportion End of treatment
Secondary
Coverage % of children eligible for treatment
(MUAC <125 mm) who receive it
Final value Proportion Mid-point of study
Defaulter Child discharged as defaulter
(3 missed visits)
Final value Proportion End of treatment
Died Child died during treatment Final value Proportion End of treatment
Length of stay Days in treatment Duration of time Sum End of treatment
Average daily weight gain g/kg/day Daily Mean End of treatment
Average daily MUAC gain mm/day Daily Mean End of treatment
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clinically managed in exactly the same way in both study
arms. The principal investigator is blinded to the treatment
outcomes, in order to maintain objective trial management
and analysis of results.
Treatment
The combined protocol will be compared against the
standard protocol (the national protocol in each country).
The combined protocol admits all children with a MUAC
<125 mm and/or oedema (+/++) and treats them accord-
ing to a standardized dose of RUTF (children with a
MUAC <115 mm or oedema receive 1000 kcal/day of
RUTF; children with a MUAC 115 to <125 mm receive
500 kcal/day of RUTF). The combined protocol remains
in line with globally accepted practice, with children recov-
ering from SAM receiving enough therapeutic food to
cover their total energy needs and children with MAM re-
ceiving a supplement to their family diet (most SFP proto-
cols provide approximately 500–550 kcal/day of RUSF).
The standard protocol includes treatment of SAM in an
OTP using RUTF (200 kcal/kg/day) and MAM in a SFP
using RUSF (500 kcal/day), as approved by the WHO,
UNICEF, WFP and Ministries of Health in each country.
The medical components of each protocol are the same,
with children in the combined protocol with a MUAC
<115 mm and/or oedema receiving the same systematic
medications as those in the standard protocol enrolled in
the OTP (per national guidelines). Children are managed
at level 1 (community) health facilities by nurses or clinical
officers for the medical aspects of care and by nutritionists
for the nutritional components. If a child requires any add-
itional medical care, they are seen by a nurse or clinical of-
ficer in the same facility. The few requiring higher level
treatment are referred to the nearest inpatient facility. The
qualifications of the staff and level of care are the same
across both arms. The combined and standard nutritional
treatment protocols are summarized in Table 1.
At each weekly follow-up visit, SAM cases are seen by a
clinician (nurse or clinical officer) for the medical review
and a nutritionist for the nutritional review. MAM cases
differ in that they return for follow-up bi-weekly and re-
ceive a medical assessment only if they exhibit signs of ill-
ness or non-response to treatment. If a child has developed
any medical complications or needs more specialist assess-
ment, they are referred to the nearest inpatient facility
(hospital in Nairobi, Kenya; Stabilization Centre in Aweil
East, South Sudan). If a child is not gaining weight or mid-
upper arm circumference appropriately, the nutritionist
will discuss with a clinician based at the health facility, ex-
ploring possible underlying medical conditions, as well as
counselling the caregiver to address possible contributory
factors (e.g. sharing of RUTF/RUSF with other children,
household food insecurity, breastfeeding for younger chil-
dren). This is the same process across both arms.
Children who miss visits are followed up by a commu-
nity health worker (Kenya) or community volunteer
(South Sudan) to encourage caretakers to return. Chil-
dren who default are followed up by a community health
worker to ascertain the child’s true status (cured, died or
remains malnourished).
Participants will be followed up 4 months post-
discharge to assess nutritional status (weight, height,
MUAC and oedema), health status (any hospitalizations
since discharge and morbidities in the prior 2 weeks), and
breastfeeding status. The objective of the follow-up study
is to assess long-term impacts of the combined protocol.
The timeline for enrolment, interventions and assess-
ments is in Fig. 2.
Outcomes
The primary outcome, ‘recovery’, in both the control and
intervention groups is defined as two consecutive mea-
surements with a MUAC ≥125 mm and no oedema. The
secondary outcomes include coverage, rates of defaulting
and death, length of stay, and average daily weight and
MUAC gain. Cost-effectiveness will be assessed through
an economic analysis of financial data following the
study. The outcome metrics are described in Table 2.
Quality control and supervision
A research officer is based in each of the 24 clinics in-
cluded in this study. Each research officer oversees the
consent process, enrolment and treatment of children
according to the study protocol and data management.
They participate in initial and refresher trainings with
health facility staff as well as provide continuous on-the-
job trainings to clinicians and community health volun-
teers involved in administering treatment according to
the study protocol. They assess the accuracy of an-
thropometric measurements taken by health facility staff
and review the patient cards and registers on a daily
basis to ensure data quality.
Research officers are supervised by a team of roving
senior supervisors, including senior research officers,
deputy manager, research field coordinator and the nu-
trition coordinator.
Data collection and management
In Kenya, patient anthropometry data is immediately tran-
scribed from paper patient cards by the research officer
based at the clinic using a digital data collection applica-
tion (CommCare HQ; https://www.commcarehq.org) on
Wi-Fi- and SIM card-enabled 7-in. Samsung Galaxy Tab
A tablets. Due to Internet connectivity challenges in South
Sudan, patient information is collected on paper first and
later transferred to a 9.6-in. Samsung Galaxy Tab E tablet
by a central data entry clerk. Data is reviewed weekly by
the field coordinators and any discrepancies corrected and
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recorded using a digital ‘data error correction form’. In
addition to the primary and secondary outcomes listed in
Table 2, additional information is collected from the care-
giver on morbidity, breastfeeding, protocol adherence,
food security, hygiene and sanitation, caretaker education
and demographic characteristics.
The procedures for assessing child anthropometry
(weight, height, MUAC and oedema) are detailed in
Additional file 1.
Analysis
Sample size calculation was determined using an ex-
pected recovery rate of 85% based on the average
programme statistics provided by the MoH in Nairobi,
Kenya, and Action Against Hunger in Aweil East, South
Sudan. If the combined protocol is non-inferior to the
current protocol, allowing for a 10% non-inferiority mar-
gin, then we require 12 clusters in each arm with 100
children in each cluster to demonstrate non-inferiority
of the combined protocol, with 80% power at the 5%
level of significance. An intra-cluster correlation coeffi-
cient (ICC) of 0.05 was assumed, a conservative estimate
based on the results of a similar cluster randomized
study testing an integrated SAM/MAM protocol in Si-
erra Leone [7]. In order to account for losses to follow-
up (estimated as 15%) and cross-overs (estimated as 5%
in each arm), 150 children per cluster will be recruited
for inclusion in the study. The cluster size calculation is
as follows: 100 × 1/(1 − 0.15) × (1/(1 − 0.05 − 0.05)2) =
146. Therefore, with a cluster size of 150, and 24
clusters, 3600 children in total will be recruited in this
study (1800 in each country).
Statistical analysis will be conducted at the individual
level with appropriate adjustment for clustering within 24
clusters. Descriptive summaries of participant characteris-
tics by arm will be tabulated. Descriptive statistics for con-
tinuous variables will include the mean, standard
deviation, median, range and the number of observations.
Categorical variables will be presented as numbers and
percentages. The main analysis of the primary and sec-
ondary outcomes will be per-protocol given that this is a
non-inferiority trial. Additionally, intention-to-treat ana-
lyses will be presented. Analyses are described in Fig. 3.
Ethics
Confidentiality
If a caretaker consents for their child to be enrolled, they
are issued a ComPAS ID number, which is affixed to their
paper forms and entered in digital forms. All patient forms
are maintained securely in a locked file throughout the
study to ensure patient confidentiality. In Kenya, data col-
lection tablets are password protected and research officers
are assigned individual logins and passwords to access the
digital data collection application (CommCare). Research
officers are able to enter data for patients at their assigned
facility only. After, the entered data is synced online to the
Fig. 2 Schedule of enrolment, interventions and assessments
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CommCare platform, which occurs daily. Research officers
cannot update prior entries unless they use an approved
data error correction form. They are able to view a very
limited selection of historical data for the purpose of pa-
tient identification and missed visit tracking. In South
Sudan, data entry tablets are password protected and data
entry clerks based in the ACF office have exclusive access
to CommCare using individual logins.
Safety
Adverse events, including hospitalizations and deaths,
are monitored and recorded by the research team for re-
view by the independent trial safety committee (de-
scribed in the ‘Trial governance’ section).
Ethical approval
This study protocol was approved by the following eth-
ical review committees:
1. Kenya Medical Research Institute (KEMRI),
Nairobi, Kenya. Reference: Non-KEMRI 551
2. Ministry of Health, Juba, South Sudan. Approved
21 November 2016
3. London School of Hygiene and Tropical Medicine,
London, UK. Reference: 11826
Trial governance
ComPAS is a research consortium of the International
Rescue Committee, Action Against Hunger and the
London School of Hygiene and Tropical Medicine. The
trial is guided by a scientific committee of experts in
paediatrics, humanitarian nutrition and epidemiology
from the London School of Hygiene and Tropical Medi-
cine, Washington University School of Medicine and the
University of Copenhagen/University of Tampere. A trial
safety committee, comprising an independent chair and
a statistician from the London School of Hygiene and
Tropical Medicine, will review the study outcomes and
adverse events at the mid-point of the trial.
This trial is registered as ISRCTN30393230, 16 March
2017 (Additional file 2).
Discussion
This study, a multi-site cluster randomized non-inferiority
trial, expected to be completed by mid-2018, is evaluating
the effectiveness of a simplified and combined treatment
protocol for SAM and MAM against the standard protocol
Assessed for eligibility (n)
Met Criteria (n)
Reasons for exclusion:
Not SAM/MAM (n) (%)
Declined consent (n) (%)
Referred to SC (n) (%)
Missing data (n) (%)
Allocated to Combined Protocol
(n clusters)
(n2  individuals)
(mean x/cluster)
Allocated to Standard Protocol
(n clusters)
(n2  individuals)
(mean x/cluster)
Per Protocol (Main Analysis)
Recovered (n)
Died (n) (included in-programme defaulter deaths 
but not late deaths who did not follow protocol)
Remained Malnourished (n)
ITT (Secondary Analysis)
Recovered (n)
Died (n) (includes early and late defaulter deaths)
Remained Malnourished (n)
Defaulter (lost to follow-up/ unknown) (n)
Defaulter (non-cure) (n)
Defaulter (cure) (n)
Fig. 3 Analysis flow chart
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of separate products (RUTF, RUSF) and programmes (OTP,
SFP) for SAM and MAM. If the results show that the com-
bined protocol has non-inferior recovery rates compared to
the standard protocol, this study will contribute to the evi-
dence that current CMAM protocols can be simplified and
that treatment of SAM and MAM can be combined (one
product, one protocol and one anthropometric criterion for
admission and discharge). This would make it easier for
health care providers to offer treatment, reaching more
children at an earlier stage before they deteriorate into se-
vere malnutrition. The results of this trial should be inter-
preted together with the cost-effectiveness analysis to
support policy decisions aimed at improving the coverage
and quality of treatment.
Trial status
Recruitment of trial participants began on 15 May 2017
and is expected to be completed by 1 June 2018, at
which point data will be analysed. The SQUEAC cover-
age assessments will be complete in both countries by
25 February 2018.
Additional files
Additional file 1: Procedures for taking anthropometric measurements.
(DOCX 14 kb)
Additional file 2: SPIRIT checklist. (DOCX 52 kb)
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